SCHEMBL1471667

SCHEMBL1471667

COc1ccc(C2=CC(=O)N(c3ccc(OC)cc3)C2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.56
MAPT P10636 4/20 0.54
BACE1 P56817 2/20 0.53
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
POLB P06746 1/20 0.50
KDM4E B2RXH2 2/20 0.49
MAPK1 P28482 2/20 0.49
PKM P14618 1/20 0.49
MCL1 Q07820 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ALDH1A1 P00352 2/20 0.47
ELANE P08246 1/20 0.45
NR1H3 Q13133 2/20 0.44
ESR1 P03372 1/20 0.44
PTPN1 P18031 1/20 0.44
APP P05067 1/20 0.43
RAB9A P51151 1/20 0.43
RAD51 Q06609 1/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471190 0.94 MAPT (0.52) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL1471737 0.94 MGLL (0.50) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL1471797 0.94 MGLL (0.50) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL1473614 0.93 MGLL (0.49) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL1471154 0.93 KDM4E (0.57) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL1471785 0.93 MGLL (0.49) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL28431988 0.92 MAPT (0.57) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL1470995 0.92 MAPT (0.60) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL1471119 0.90 LMNA (0.49) MGLLMAPTBACE1MEN1KMT2A
SCHEMBL10883619 0.89 MGLL (0.45) MGLLMAPTBACE1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MGLL 857/4885MAPT 1947/4885BACE1 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.